Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome

American Journal of Psychiatry

Volumn 151, Issue 12, 1994, Pages 1744-1752

  Lieberman, Jeffrey A ^a   Safferman, Allan Z ^b   Pollack, Simcha ^b   Szymanski, Sally ^b   Johns, Celeste ^b   Howard, Alfreda ^b   Kronig, Michael ^b   Bookstein, Peter ^b   Kane, John M ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENDER; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; ORAL DRUG ADMINISTRATION; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL;

EID: 0028007550     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.151.12.1744     Document Type: Article

References (53)

1. Burki HR, Eichenberger E, Sayers AC, White TG: Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal. Pharmakopschiatr-Neuropsychopharmakol 1975; 8:115-121
2. Bartholini G, Haefely W, Jalfre M, Keller HH, Pletscher A: Effects of clozapine on cerebral catecholaminergic neurone systems. Br J Pharmacol 1972; 46:736-740
3. Kelly PH, Iversen SD: Selective 60HDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 1976; 40:45-56
4. Halperin R, Guerin JJ, Davis KL: Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. Psychopharmacology (Berl) 1989; 98: 386-391
5. Coward DM, Imperato A, Urwyler S, White TG: Biochemical and behavioural properties of clozapine. Psychopharmacology (Berl) 1989; 99(suppl):S6-S12
6. Chiu E, Burrows G, Stevenson J: Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness. Aust NZ J Psychiatry 1976; 10:343-347
7. Ekblom B, Haggstrom JE: Clozapine compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 1974; 16:945-967
8. Guirguis E, Voineskos G, Gray J, Schlieman E: Clozapine (Leponex) vs chlorpromazine (Largactil) in acute schizophrenia (a double-blind controlled study). Curr Ther Res 1977; 21:707-719
9. Leon CA, Estrada H: Therapeutic effect of clozapine on psychotic symptoms (clinical evaluation using the double-blind method). Revista Columbiana de Psiquiatria 1974; 3:309-320
10. Niskanen P, Achte K, Jaskari M, Karesoja M, Melsted B, et al: Results of a comparative double-blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients. Psychiatria Fennica 1974:307-313
11. Singer K, Law SK: A double-blind comparison of clozapine (Leponex) and chlorpromazine in schizophrenia of acute symptomatology. J Int Med Res 1974; 2:433-435
12. Vencovsky E, Peterova E, Baudis P: A comparison of the therapeutic effects of clozapine and chlorpromazine. Cesk Psychiatr 1975; 71:21-26
13. Gerlach J, Koppelhus P, Helweg E, Monrad A: Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 1974; 50:410-424
14. Itoh H, Miura S, Yagi G, Sakurai S, Ohtsuka N: Some methodological considerations for the clinical evaluation of neuroleptics - comparative effects of clozapine and haloperidol on schizophrenics. Folia Psychiatr Neurol Jpn 1977; 31:17-24
15. Angst J, Jaenicke U, Padrutt A, Schafotter CH: Results of a double-blind study of HF 1854 (8-chloro-11-(4-methyl-1-piperizynl)-5H-dibenzo(b,e)(1,4)-diazepine compared to levomepromazine, Pharmacopsychiatry 1971; 4:192-200
16. Rodova A, Svestka J, Nahunek K, Ceskova E: A blind comparison of clozapine and perphenazine in schizophrenics. Act Nerv Super (Praha) 1973; 15:94-95
17. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
18. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-384
19. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J: A prospective study of clozapine in treatment-resistant schizophrenic patients, I: preliminary report. Psychopharmacology (Berl) 1989; 99(suppl):S68-S72
20. Mattes JA: Clozapine for refractory schizophrenia: an open study of 14 patients treated up to two years. J Clin Psychiatry 1989; 50:389-391
21. Owen RR, Beake BJ, Marby D, Dessain EC, Cole JO: Response to clozapine in chronic psychotic patients. Psychopharmacol Bull 1989; 25:253-256
22. Small JG, Milstein V, Marhenke JD, Kellams JJ: Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987; 48:263-267
23. Naber D, Leppig M, Grohmann R, Hippius H: Efficacy and adverse effects in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients. Psychopharmacology (Berl) 1989; 99(suppl):S73-S76
24. Clozapine Study Group: The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psychiatry 1993; 163:150-154
25. Lindstrom LH: The effect of long-term treatment of clozapine in schizophrenia: a retrospective study of 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77: 524-529
26. Meltzer HY, Burnett S, Bastani B, Ramirez LF: Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892-897
27. Meltzer HY: Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160(suppl 17):46-53
28. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR: The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993; 162:43-48
29. Meltzer HY: Duration of a clozapine trial in neuroleptic-resistant schizophrenia (letter). Arch Gen Psychiatry 1989; 46:672
30. Casey DE: Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989; 99(suppl):S47-S53
31. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J: The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158:503-510
32. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
33. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
34. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
35. Lieberman J, Kane J, Woerner M, Weinhold P, Basavaraju N, Kurucz J, Bergmann K: Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull 1984; 20:382-386
36. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
37. Benedetti J, Yuen K, Young L: Life tables and survival functions, in BMDP Statistical Software. Edited by Dixon WJ. Berkeley, University of California Press, 1985, pp 557-575
38. Tarone RE, Ware J: On distribution-free tests for equality of survival distributions. Biometrika 1977; 64:156-160
39. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170
40. Cox DR: Regression models and life tables. J Royal Statistical Society 1972; 34(series B):187-220
41. Safferman AZ, Lieberman JA, Pollack S, Kane JM: Clozapine and akathisia. Biol Psychiatry 1992; 31:753-754
42. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM: HLA B-38, DR4, DqW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47: 945-948
43. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis: US incidence and risk factors. N Engl J Med 1993; 329:162-167
44. Pickar D, Owen RR, Litman RE, Konicki PE, Guitierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia. Arch Gen Psychiatry 1992; 43:345-353
45. Carpenter WT, Heinrichs DW, Alphs LD: Treatment of negative symptoms. Schizophr Bull 1985; 11:440-452
46. Meltzer HY: Pharmacologic treatment of negative symptoms, in Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Edited by Greden JF, Tandon R. Washington, DC, American Psychiatric Press, 1991
47. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC: Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35:8-15
48. Wyatt RJ: Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res 1991; 5: 201-202
49. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149:1183-1188
50. Lieberman JA, Kinon BJ, Loebel AD: Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 1990; 16:97-110
51. Fenton WS, McGlashan TH: Natural history of schizophrenia subtypes, I: longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry 1991; 48: 969-977
52. Pfohl B, Winokur G: The evolution of symptoms in institutionalized hebephrenic/catatonic schizophrenics. Br J Psychiatry 1982; 144:5767-5772
53. Honigfeld G, Patin J: Predictors of response to clozapine therapy. Psychopharmacology (Berl) 1989; 99(suppl):S64-S67